Inflammation is a major risk factor for the development of cystoid macular oedema (CMO) after cataract surgery, leading to breakdown of the blood-retina barrier. There is a correlation between severity of CMO and level of postoperative inflammation. Laser flare meter (LFM) is used to quantify the amount of inflammation in the anterior chamber in this single-centre double-blind randomised trial. Sixty-four patients were included in the study. Both Diclofenac (four times daily for four weeks) and Nepafenac (three times daily for three weeks) were effective in controlling anterior chamber flare, but Nepafenac was significantly more effective than Diclofenac at 15 and 30 days after surgery. Macular thickness didn’t vary between the two groups in this study.